

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5077667

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the ASSIGNMENT ITSELF WHICH WAS PREVIOUSLY ATTACHED TO ORIGINAL RECORDATION (BY REMOVING THE COMMA IN RECEIVING PARTY NAME) previously recorded on Reel 042246 Frame 0703. Assignor(s) hereby confirms the ASSIGNMENT OF THE ENTIRE RIGHT, TITLE AND INTEREST.
CONVEYING PARTY DATA	
Name	Execution Date
1ST ORDER PHARMACEUTICALS, INC.	07/31/2018
RECEIVING PARTY DATA	
Name:	XENON PHARMACEUTICALS INC.
Street Address:	200 - 3650 GILMORE WAY
City:	BURNABY
State/Country:	CANADA
Postal Code:	V5G 4W8
PROPERTY NUMBERS Total: 4	
Property Type	Number
Patent Number:	8293911
Patent Number:	8993593
PCT Number:	US0718571
PCT Number:	US1122345
CORRESPONDENCE DATA	
Fax Number:	(206)682-6031
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2066224900
Email:	carolw@seedip.com
Correspondent Name:	CAROL J. ROTH
Address Line 1:	701 FIFTH AVENUE
Address Line 2:	SUITE 5400
Address Line 4:	SEATTLE, WASHINGTON 98104-7092
ATTORNEY DOCKET NUMBER:	980057.503 FAMILY - US
NAME OF SUBMITTER:	CAROL J. ROTH
SIGNATURE:	/Carol J. Roth/
DATE SIGNED:	08/01/2018

Total Attachments: 6

source=980057_503_FAMILY___Corrective_Assignment_US_only#page1.tif

source=980057_503_FAMILY___Corrective_Assignment_US_only#page2.tif

source=980057_503_FAMILY___Corrective_Assignment_US_only#page3.tif

source=980057_503_FAMILY___Corrective_Assignment_US_only#page4.tif

source=980057_503_FAMILY___Corrective_Assignment_US_only#page5.tif

source=980057_503_FAMILY___Corrective_Assignment_US_only#page6.tif

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT										
NATURE OF CONVEYANCE:	ASSIGNMENT										
CONVEYING PARTY DATA											
<table border="1"><tr><th>Name</th><th>Execution Date</th></tr><tr><td>1ST ORDER PHARMACEUTICALS, INC.</td><td>04/21/2017</td></tr></table>	Name	Execution Date	1ST ORDER PHARMACEUTICALS, INC.	04/21/2017							
Name	Execution Date										
1ST ORDER PHARMACEUTICALS, INC.	04/21/2017										
RECEIVING PARTY DATA											
<table border="1"><tr><td>Name:</td><td>XENON PHARMACEUTICALS INC.</td></tr><tr><td>Street Address:</td><td>200 - 3650 GILMORE WAY</td></tr><tr><td>City:</td><td>BURNABY</td></tr><tr><td>State/Country:</td><td>CANADA</td></tr><tr><td>Postal Code:</td><td>V5G 4W8</td></tr></table>	Name:	XENON PHARMACEUTICALS INC.	Street Address:	200 - 3650 GILMORE WAY	City:	BURNABY	State/Country:	CANADA	Postal Code:	V5G 4W8	
Name:	XENON PHARMACEUTICALS INC.										
Street Address:	200 - 3650 GILMORE WAY										
City:	BURNABY										
State/Country:	CANADA										
Postal Code:	V5G 4W8										
PROPERTY NUMBERS Total: 4											
<table border="1"><tr><th>Property Type</th><th>Number</th></tr><tr><td>Patent Number:</td><td>8293911</td></tr><tr><td>Patent Number:</td><td>8993593</td></tr><tr><td>PCT Number:</td><td>US0718571</td></tr><tr><td>PCT Number:</td><td>US1122345</td></tr></table>	Property Type	Number	Patent Number:	8293911	Patent Number:	8993593	PCT Number:	US0718571	PCT Number:	US1122345	
Property Type	Number										
Patent Number:	8293911										
Patent Number:	8993593										
PCT Number:	US0718571										
PCT Number:	US1122345										
CORRESPONDENCE DATA											
<p>Fax Number: (206)682-6031 Phone: 2066224900 Email: carolw@seedip.com <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> Correspondent Name: CAROL J. ROTH Address Line 1: 701 FIFTH AVENUE Address Line 2: SUITE 5400 Address Line 4: SEATTLE, WASHINGTON 98104-7092</p>											
ATTORNEY DOCKET NUMBER:	980057.503 FAMILY - US										
NAME OF SUBMITTER:	CAROL J. ROTH										
Signature:	/Carol J. Roth/										

Date:	05/04/2017
Total Attachments: 4 source=980057_503_family_US_Assignment#page1.tif source=980057_503_family_US_Assignment#page2.tif source=980057_503_family_US_Assignment#page3.tif source=980057_503_family_US_Assignment#page4.tif	
RECEIPT INFORMATION EPAS ID: PAT4399384 Receipt Date: 05/04/2017	

CSC July 31, 2018

PATENT ASSIGNMENT

Xenon Pharmaceuticals Inc.

THIS PATENT ASSIGNMENT (this "Patent Assignment") from 1st Order Pharmaceuticals, Inc., a Delaware corporation ("Assignor") to ~~Xenon Pharmaceuticals, Inc.~~, a corporation continued under the federal laws of Canada ("Assignee"), is effective as of April 25, 2017.

WHEREAS, Assignor and Assignee have entered into an Asset Purchase Agreement, dated as of April 25, 2017 (the "Purchase Agreement"), pursuant to which, among other things, Assignor has agreed to assign to Assignee the Assigned Patents (as defined below).

1. Assigned Patents. The term "Assigned Patents" means the issued patents and pending patent applications set forth on Schedule A attached hereto.

2. Assignment. For good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, Assignor hereby irrevocably assigns, transfers, sells and delivers to Assignee all of Assignor's right, title and interest in and to (i) the Assigned Patents and the inventions and improvements disclosed therein; (ii) all reissues, divisionals, continuations, continuations-in-part, extensions, renewals, reexaminations and foreign counterparts thereof; (iii) all patents and applications which claim priority to or have common priority with any such patents or patent applications; and (iv) all rights corresponding to any of the foregoing throughout the world, including the right to claim priority from any of the Assigned Patents, the right to prosecute and maintain any of the Assigned Patents, and the right to sue, claim remedies and recover damages for past, present and future infringement or other violation or impairment of any of the Assigned Patents, the same to be held and enjoyed by Assignee for its own use and enjoyment, and for the use and enjoyment of its successors, assigns and other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor, if this assignment and sale had not been made.

3. Representations and Warranties. Assignor represents and warrants that, as of the date hereof: (i) Assignor owns the Assigned Patents; (ii) Assignor has the power and authority to execute this Patent Assignment; (iii) Assignor has not entered into any agreement that conflicts with the terms of this Patent Assignment.

4. Further Assurances. Assignor agrees that Assignee shall have the right to file or record this Patent Assignment with the United States Patent and Trademark Office or other such entities throughout the world, and Assignor authorizes and requests the relevant authorities to record Assignee as the assignee and owner of the Assigned Patents. Assignor shall execute and deliver to Assignee such documents and take such actions as requested by Assignee to register, evidence or perfect Assignee's rights under this Patent Assignment. In addition, Assignor hereby irrevocably designates and appoints Assignee and its duly authorized officers and agents as its agents and attorneys in fact, to act for and on their behalf and stead to execute and file any such documents and to do all other lawfully permitted acts to register, evidence or perfect Assignee's rights under this Patent Assignment with the same legal force and effect as if executed by Assignor. This includes, but is not limited to, the power to insert on this Patent Assignment any further identification that may be necessary to comply with the rules of the

United States Patent and Trademark Office, or rules of other entities throughout the world, for recordation of this document.

5. Governing Law. This Patent Assignment shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of choice or conflicts of law thereof.

[The remainder of this page is intentionally left blank; signature page follows.]

EXECUTION VERSION

IN WITNESS WHEREOF, Assignor has caused this Patent Assignment to be executed as of the date first written above by its duly authorized officer.

ASSIGNOR:

1st ORDER PHARMACEUTICALS, INC.

By: [Signature]

Name: Christopher S. Crean

Title: President & CEO

ACKNOWLEDGMENT


State of North Carolina
County of Wake } ss:

On this 21st day of April 2017, before me, the undersigned, personally appeared Christopher S. Crean, personally known to me or proved to me on the basis of satisfactory evidence to be the person who executed this instrument on behalf of the corporation named herein, and acknowledged that s/he executed it in such representative capacity.

IN WITNESS WHEREOF, I have hereunto set my hand and official seal.

[Signature]
Notary Public Lori J. Fryar

My Commission Expires on 11-20-2019



[SIGNATURE PAGE TO U.S. PATENT ASSIGNMENT]

SCHEDULE A

ASSIGNED PATENTS

Inventors for the US 8,293,911 Patent Family: Jean-Michel Vernier, Laguna Niguel, CA (US); Martha Alicia De La Rosa, San Diego, CA (US); Huanming Chen, Irvine, CA (US); Jim Zhen Wu, Aliso Viejo, CA (US); Gary Lee Larson, Cypress, CA (US); Ian Wayne Cheney, Mission Viejo, CA (US)

Inventors for the US 8,993,593 Patent Family: Jean-Michel Vernier, Laguna Niguel, CA (US); Martha Alicia De La Rosa, San Diego, CA (US); Huanming Chen, Irvine, CA (US); Jim Zhen Wu, Aliso Viejo, CA (US); Gary Lee Larson, Cypress, CA (US); Ian Wayne Cheney, Mission Viejo, CA (US)

Brinks Gilson Leoni Reference	Country	Title	App. Date	App. No.	Pub Date	Pub No.	Issued Date	Patent No.	Status
15709-16	US	DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS	01-Feb-2010	12/698,070	Jan 6, 2011	US 2011-00038 50 A1	31 March 2015	8,993,593	Issued
15709-17	PCT	DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS	25-Jan-2011	PCT/US2011/022345	4-Aug-2011	WO2011/094186 A1			Entered national phase, completed
15709-18	US	DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS	22-Aug-2007	11/894,877	12-Jun-2008	US 2008-01396 10 A1	Oct 23 2012	US 8,293,911 B2	Issued
15709-19	PCT	DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS	22-Aug-2007	PCT/US2007/018571	28-Feb-2008	WO2008/024398 B1			Entered national phase, Completed